MTOR and breast carcinoma: Although PI3K–AKT–mTOR signaling blockade is a promising therapeutic strategy for breast cancer, predicting patient response using biomarkers has remained challenging, which has compromised the effectiveness of these targeted therapies (Lee et al., 2015; Yi and Ma, 2017).